Recent advances in the discovery of selective and non-selective 5-HT 1D receptor ligands

Current Topics in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 479-492

  Ward, Simon E ^a   Watson, Jeannette M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT receptor; 5 HT1d agonist; 5 HT1d antagonist; Serotonin receptor

Indexed keywords

1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 4 [1 (2 DIMETHYLAMINOETHYL) 1H INDOL 6 YL]TETRAHYDROTHIOPYRAN 4 OL; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ALMOTRIPTAN; ALX 0646; ELETRIPTAN; ELZASONAN; EMD 135894; FROVATRIPTAN; LY 367642; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; PARTIAL AGONIST; PLACEBO; RIZATRIPTAN; SB 272183; SB 616234; SB 649915; SB 714786; SEROTONIN 1D AGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TGBA 01 AD; TREXIMET; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILAZODONE; ZOLMITRIPTAN;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HALOGENATION; HUMAN; MAJOR DEPRESSION; MIGRAINE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

DRUG DISCOVERY; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950577161     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791111533     Document Type: Article

References (86)

1. Dawson L. A.; Bromidge, S. M. 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. Curr. Top. Med. Chem., 2008, 8, 1008-1023.
2. Butler, S. G.; Meegan, M. J. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr. Med. Chem., 2008, 15, 1737-1761.
3. Schechter, L. E.; Ring, R. H.; Beyer, C. E.; Hughes, Z. A.; Khawaja, X.; Malberg, J. E.; Rosenzweig-Lipson, S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx., 2005, 2, 590-611.
4. Farnebo, L. O.; Hamberger, B. Regulation of (3H)5-hydroxytryptamine release from rat brain slices. J. Pharm. Pharmacol., 1974, 26, 642-644.
5. Duncan, M. J.; Jennes, L.; Jefferson, J. B.; Brownfield, M. S. Localization of serotonin(5A) receptors in discrete regions of the circadian timing system in the Syrian hamster. Brain Res., 2000, 869, 178-185.
6. To, Z. P.; Bonhaus, D. W.; Eglen, R. M.; L. B. Jakeman, Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain. Br. J. Pharmacol, 1995, 115, 107-116.
7. Slassi, A. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr. Top. Med. Chem., 2002, 2, 559-574.
8. Panconesi, A. Serotonin and migraine: a reconsideration of the central theory. J. Headache Pain, 2008, 9, 267-276.
9. Bateman, D. N. Triptans and migraine. Lancet, 2000, 355, 860-861.
10. Selkirk, J. V.; Scott, C.; Ho, M.; Burton, M. J.; Watson, J.; Gaster, L. M.; Collin, L.; Jones, B. J.; Middlemiss, D. N.; Price, G. W. SB-224289-a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol., 1998, 125, 202-208.
11. Scott, C. Langmead, C. J.; Clarke, K. L.; Wyman, P.; Smith, P. W.; Starr, K. R.; Dawson, L. A.; Price, G. W.; Hagan, J. J.; Watson, J. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro5-methoxyindol-1-yl]-l- [2′methyl-4′-(5-methyl-1,2,3-oxadiazol-3yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1.B receptor antagonist. Neuropharmacology, 2006, 50, 984-990.
12. Roberts, C.; G. W. Price, Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: an in vitro fast cyclic voltammetry study. Neurosci. Lett., 2001, 300, 45-48.
13. Middlemiss, D. N.; Gothert, M.; Schlicker, E.; Scott, C. M.; Selkirk, J. V.; Watson, J.; Gaster, L. M.; Wyman, P.; Riley, G.; Price, G. W. SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal, autoreceptor. Eur. J. Pharmacol, 1999, 575, 359-365.
14. Pullar, I. A.; Boot, J. R.; Broadmore, R. J.; Eyre, T. A.; Cooper, J.; Sanger, G. J.; Wedley, S.; Mitchell, S. N. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur. J. Pharmacol, 2004, 493, 85-93.
15. Marcoli, M.; Maura, G.; Munari, C.; Ruelle, A.; Raiteri, M. Pharmacological diversity between native human 5-HT1B and 5HTlD receptors sited on different neurons and involved in different functions. Br. J. Pharmacol, 1999, 126, 607-612.
16. Schlicker, E.; Fink, K.; Molderings, G. J.; Price, G. W.; Duckworth, M.; Gaster, L.; Middlemiss, D. N.; Zentner, J.; Likungu, J.; Gothert, M. Effects of selective h5-HT1B (SB216641) and h5-HT1D (BRL-15572) receptor ligands on guineapig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch. Pharmacol, 1997, 356, 321-327.
17. Manuel, N. A.; Wallis, D. I.; Crick, H. Ketanserin-sensitive depressant actions of 5-HT receptor agonists in the neonatal rat spinal cord. Br. J. Pharmacol, 1995, 116, 2647-2654.
18. Honda, M.; Imaida, K.; Tanabe, M.; Ono, H. Endogenously released 5-hydroxytryptamine depresses the spinal monosynaptic reflex via 5-HT1D receptors. Eur. J. Pharmacol, 2004, 503, 55-61.
19. Oades, R. D. Role of the serotonin system in ADHD: treatment implications. Expert. Rev. Neurother., 2007, 7, 1357-1374.
20. Li, J.; Zhang, X.; Wang, Y.; Zhou, R.; Zhang, H.; Yang, L.; Wang, B.; Faraone, S. V. The serotonin 5-HT1D receptor gene and attention-deficit hyperactivity disorder in Chinese Han subjects. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2006, 141B, 874-876.
21. Harriott, A. M.; Gold, M. S. Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia, 2008, 28, 933-944.
22. Ahn, A. H.; Basbaum, A. I. Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain. J. Neurosci., 2006, 826, 332-8338.
23. Tfelt-Hansen, P.; de Vries, P.; Saxena, P. R.Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs, 2000, 60, 1259-1287.
24. Humphrey, P. P. The discovery and development of the triptans, a major therapeutic breakthrough. Headache, 2008, 48, 685-687.
25. Humphrey, P. P. The discovery of a new drug class for the acute treatment of migraine. Headache, 2007, 47, (Suppl 1) S10-S19.
26. Filla, S. A.; Mathes, B. M.; Johnson, K. W.; Phebus, L. A.; Cohen, M. L.; Nelson, D. L.; Zgombick, J. M.; Erickson, J. A.; Schenck, K. W.; Wainscott, D. B.; Branchek, T. A.; Schaus, M. Novel, potent 5HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4- piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides. J. Med. Chem., 2003, 46, 3060-3071.
27. Xu, Y. C.; Johnson, K. W.; Phebus, L. A.; Cohen, M.; Nelson, D. L.; Schenck, K.; Walker, C. D.; Fritz, J. E.; Kaldor, S. W.; LeTourneau, M. E.; Murff, R. E.; Zgombick, J. M.; Calligaro, D. O.; Audia, J. E.; Schaus, J. M. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy. J. Med. Chem., 2001, 44, 4031-4034.
28. Goldstein, D. J.; Roon, K. I.; Offen, W. W.; Ramadan, N. M.; Phebus, L. A.; Johnson, K. W.; Schaus, J. M.; Ferrari, M. D. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised, controlled, trial. Lancet, 2001, 358, 1230-1234.
29. Shepheard, S.; Edvinsson, L.; Cumberbatch, M.; Williamson, D.; Mason, G.; J.; Webb, S. Boyce, R. Hill, and R. Hargreaves, Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia, 1999, 19, 851-858.
30. Slassi, A.; Edwards, L.; O'Brien, A.; Meng, C. Q.; Xin, T.; Seto, C.; Lee, D. K.; MacLean, N.; Hynd, D.; Chen, C.; Wang, H.; Kamboj, R.; Rakhit, S.; 5-Alkyltryptamine derivatives as highly selective and potent 5-HTlD receptor agonists. Bioorg. Med. Chem. Lett., 2000, 10, 1707-1709.
31. Xu, Y. C.; Schaus, J. M.; Walker, C.; Krushinski, J.; Adham, N.; Zgombick, J. M.; Liang, S. X.; Kohlman, D. T.; Audia, J. E. N-Methyl-5-tert- butyltryptamine: A novel, highly potent 5-HT1D receptor agonist. J. Med. Chem., 1999, 42, 526-531.
32. Egle, I.; MacLean, N.; Demchyshyn, L.; Edwards, L.; Slassi, A.; Tehim, A. (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1 H-indole derivatives as high affinity h5-HT1B/1D ligands. Bioorg. Med. Chem. Lett., 2003, 13, 3419-3421.
33. Isaac, M.; Slassi, A. Recent advances in 5-HT(lD)-selective agonists. IDrugs., 2001, 4, 189-196.
34. Terzioglu, N.; Holtje, H.-D. Receptor-based 3D QSAR analysis of serotonin 5-HT1D receptor agonists. Coll. Czech. Chem. Commun., 2005, 70, 1482-1492.
35. Choi, S. K.; Green, D.; Ho, A.; Klein, U.; Marquess, D.; Taylor, R.; Turner, S. D. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4- piperidinyl)-1H-indol-5-yl]benzamide. J. Med. Chem., 2008, 51, 3609-3616.
36. Perez, M.; Jorand-Lebrun, C.; Pauwels, P. J.; Pallard, I.; Halazy, S. Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes. Bioorg. Med. Chem. Lett., 1998, 8, 1407-1412.
37. Slassi, A. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr. Top. Med. Chem., 2002, 2, 559-574.
38. Torrado, A.; Lamas, C.; Agejas, J.; Jimenez, A.; Diaz, N.; Gilmore, J.; Boot, J.; Findlay, J.; Hayhurst, L.; Wallace, L.; Broadmore, R.; Tomlinson, R. Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg. Med. Chem., 2004, 12, 5277-5295.
39. Timms, G. H.; Boot, J. R.; Broadmore, R. J.; Carney, S. L.; Cooper, J.; Findlay, J. D.; Gilmore, J.; Mitchell, S.; Moore, N. A.; Pullar, I.; Sanger, G. J.; Tomlinson, R.; Tree, B. B.; Wedley, S. SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis. Bioorg. Med. Chem. Lett., 2004, 14, 2469-2472.
40. Agejas-Chicharro, Javier, Bueno Melendo, Ana Belen, Camp, Nicholas Paul, Gilmore, Jeremy, Lamas-Peteira, Carlos, Timms, Graham. Henry, and Williams, Andrew Caerwyn. Preparation of isochromans and related compounds as selective serotonin reuptake inhibitors for treatment of CNS disorders. WO 2003053948, 2003.
41. Agejas-Chicharro, Javier, Bueno Melendo, Ana Belen, Camp, Nicholas Paul, Gilmore, Jeremy, Jimenez-Aguado, Alma Maria, Lamas-Peteira, Carlos, Marcos-Llorente, Alicia, Mazanetz, Michael Philip, Montero Salgado, Carlos, Timms, Graham Henry, and Williams, Andrew. Preparation of heterocyclyl- piperidinyl/ piperazinyl-isochromans as CNS agents. WO 2002050067, 2002.
42. Rollema, H.; Clarke, T.; Sprouse, J. S.; Schulz, D. W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem., 1996, 67, 2204-2207.
43. Ennis, M. D.; Ghazal, N. B.; Hoffman, R. L.; Smith, M. W.; Schlachter, S. K.; Lawson, C. F.; Im, W. B.; Pregenzer, J. P.; Svensson, K. A.; Lewis, R. A.; Hall, E. D.; Sutter, D. M.; Harris, L. T.; McCall, R. B. Isochroman-6- carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects. J. Med. Chem., 1998, 41, 2180-2183.
44. Torrado, A.; Lamas, C.; Agejas, J.; Jimenez, A.; Diaz, N.; Gilmore, J.; Boot, J.; Findlay, J.; Hayhurst, L.; Wallace, L.; Broadmore, R.; Tomlinson, R. Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg. Med. Chem., 2004, 12, 5277-5295.
45. Bueno, A. B.; Gilmore, J.; Boot, J.; Broadmore, R.; Cooper, J.; Findlay, J.; Hayhurst, L.; Marcos, A.; Montero, C.; Mitchell, S.; Timms, G.; Tomlinson, R.; Wallace, L.; Walton, L. Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3344-3348.
46. Agejas-Chicharro, Javier, Bueno Melendo, Ana Belen, Camp, Nicholas Paul, Gilmore, Jeremy, Lamas-Peteira, Carlos, Timms, Graham Henry, and Williams, Andrew Caerwyn. Preparation of isochromans and related compounds as selective serotonin reuptake inhibitors for treatment of CNS disorders. WO 2003053948. 2003.
47. Atkinson, P. J.; Bromidge, S. M.; Duxon, M. S.; Gaster, L. M.; Hadley, M. S.; Hammond, B.; Johnson, C. N.; Middlemiss, D. N.; North, S. E.; Price, G. W.; Rami, H. K.; G. J. Riley, Scott, C. M.; Shaw, T. E.; Starr, K. R.; Stemp, G.; Thewlis, K. M.; Thomas, D. R.; Thompson, M.; Vong, A. K.; Watson, J. M.3,4-D.ihydro-2Hbenzoxaz.inones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett., 2005, 15, 737-741.
48. Scott, C.; Soffln, E. M.; Hill, M.; Atkinson, P. J.; Langmead, C. J.; Wren, P. B.; Faedo, S.; Gordon, L. J.; Price, G. W.; Bromidge, S.; Johnson, C. N.; Hagan, J. J.; Watson, J.SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. Eur. J. Pharmacol, 2006, 536 54-61.
49. Ward, S. E.; Johnson, C. N.; Lovell, P. J.; Scott, C. M.; Smith, P. W.; Stemp, G.; Thewlis, K. M.; Vong, A. K.; Watson, J. M. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands. Bioorg. Med. Chem. Lett, 2007, 17, 5214-5217.
50. Skingle, M.; Beattie, D. T.; Scopes, D. I.; Starkey, S. J.; Connor, H. E.; Feniuk, W.; Tyers, M. B. GR127935: a potent and selective 5-HT1D receptor antagonist. Behav. Brain Res., 1996, 73, 157-161.
51. Skingle, M.; Sleight, A. J.; Feniuk, W. Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology, 1995, 34, 377-382.
52. Lovell, P. J.; Goodacre, C. J.; Smith, P. W.; Scott, C. M.; Starr, K. R.; Thewlis, K. M.; Vong, A. K. K.; Ward, S. E.; Watson, J. M. 3,4-dihydro-2H- benzoxazinones as dual-acting 5HT1A receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 1033-1036.
53. Ward, S. E.; Eddershaw, P. J.; Scott, C. M.; Gordon, L. J.; Lovell, P. J.; Moore, S. H.; Smith, P. W.; Starr, K. R.; Thewlis, K. M.; Watson, J. M. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists. J. Med. Chem., 2008, 51, 2887-2890.
54. Ward, S. E.; Eddershaw, P.; Flynn, S. T.; Gordon, L.; Lovell, P. J.; Moore, S. H.; Scott, C. M.; Smith, P. W.; Thewlis, K. M.; Wyman, P. A. Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands-part II, Bioorg. Med. Chem. Lett., 2009, 19, 428-432.
55. Vong, Antonio Kuok Keong and Ward, Simon Edward. Benzoxazinone derivatives, their preparation and use. WO 2004099196. 2004.
56. Vong, Antonio Kuok Keong and Ward, Simon Edward. Preparation of benzoxazinone derivatives having affinity for 5-HT receptors. 2004, WO 2004099198.
57. Flynn, Sean Thomas, Smith, Paul W., Thewlis, Kevin Michael, Ward, Simon E., and. Wyman, Paul Adrian. Piperidine and piperazine derivatives possessing affinity at 5HT-1 type receptors, and their preparation, pharmaceutical, compositions, and use in the treatment of CNS disorders. 2003. WO 2003068236.
58. Smith, Paul W., Thewlis, Kevin Michael, Vong, Antonio Kuok Keong, and Ward, Simon E. Preparation of (hetero)aryloxyethylpiperidines possessing affinity at 5HT1-type receptors. 2003. WO 2003068760.
59. Ward, Simon. E. Preparation, of heterocyclylmethylpiperidines and piperazine s possessing affinity at 5-HT1 type receptors. 2003. WO 2003068771.
60. Harrington, Frank Peter, Smith, Paul William, and Ward, Simon E. Preparation of heterocyclic compounds possessing affinity at 5-HT1-type receptors and uses thereof in therapy. 2003. WO 2003068772.
61. Heightman, T. D.; Gaster, L. M.; Pardoe, S. L.; Pilleux, J. P.; Hadley, M. S.; Middlemiss, D. N.; Price, G. W.; Roberts, C.; Scott, C. M.; Watson, J. M.; Gordon, L. J.; Holland, V. A.; Powles, J.; Riley, G. J.; Stean, T. O.; Trail, B. K.; Upton, N.; Austin, N. E.; Ayrton, A. D.; Coleman, T.; Cutler, L. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands. Bioorg. Med. Chem, Lett., 2005, 15, 4370-4374.
62. Watson, J.; Roberts, C.; Scott, C.; Kendall, I.; Collin, L.; Day, N. C.; Harries, M. H.; Soffin, E.; Davies, C. H.; Randall, A. D.; Heightman, T.; Gaster, L.; Wyman, P.; Parker, C.; Price, G. W.; Middlemiss, D. N. SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br. J. Pharmacol, 2001, 133, 797-806.
63. Serafinowska, H. T.; Blaney, F. E.; Lovell, P. J.; Merlo, G. G.; Scott, C. M.; Smith, P. W.; Starr, K. R.; Watson, J. M. Novel 5-HT(1A/1B/1D) receptors antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett., 2008, 18, 5581-5585.
64. Bromidge, S. M.; Bertani, B.; Borriello, M.; Faedo, S.; Gordon, L. J.; Granei, E.; Hill, M.; Marshall, H. R.; Stasi, L. P.; Zucchelli, V.; Merlo, G.; Vesentini, A.; Watson, J. M.; Zonzini, L. 6-[2-(4-Aryl1-piperazinyl)ethyl]-2H-1, 4-benzoxazin-3(4H)-ones: dual-acting 5HT1 receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5653-5656.
65. Bergauer, Markus, Bertani, Barbara, Biagetti, Matteo, Bromidge, Steven Mark, Falchi, Alessandro, Leslie, Colin. Philip, Merlo, Giancarlo, Pizzi, Domenica Antonia, Rinaldi, Marilisa, Stasi, Luigi Piero, Tibasco, Jessica, Vong, Antonio Kuok Keong, and Ward, Simon. Preparation of quinolines and quinazolines as ligands for 5-HT1 receptors and their use in the treatment of CNS disorders, in particular serotonin-related disorders. 2005. WO 2005014552.
66. Bertani, Barbara, Bordello, Manuela, Bozzoli, Andrea, Bromidge, Steven Mark, Granei, Enrica, Leslie, Colin, Serafinowska, Halina, Stasi, Luigi, Vong, Antonio, and Zucchelli, Valeria. Preparation of benzoxazinones as ligands for 5-HT1 receptors and their use in the treatment of CNS disorders, in particular serotonin-related disorders. 2004. WO 2004046124.
67. Huang, Y.; Bae, S. A.; Roth, B. L.; Laruelle, M. Synthesis of potent and selective serotonin 5-HT1B receptor ligands, Bioorg. Med. Chem. Lett., 2005, 15, 4786-4789.
68. Ward, S. E.; Harrington, F. P.; Gordon, L. J.; Hopley, S. C.; Scott, C. M.; Watson, J. M. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J. Med. Chem., 2005, 48, 3478-3480.
69. Schiemann, Kai, Boettcher, Henning, Heinrich, Timo, Hoelzemann, Guenter, Van Amsterdam, Christoph, Bartoszyk, Gerd, Leibrock, Joachim, and Seyfried, Christoph. Preparation of piperazinylalkylindoles as 5-HT1A and/or 5-HT1D agonists and as 5-HT reuptake inhibitors. 2004. WO2004041815.
70. Schiemann, Kai, Boettcher, Henning, Heinrich, Timo, Hoelzemann, Guenter, Van Amsterdam, Christoph, Bartoszyk, Gerd, Leibrock, Jochim, and Seyfried, Christoph. Preparation of chromenonindole derivatives as 5-HTx agonistics and/or antagonistics. 2004. WO2004087692.
71. Hoelzemann, Guenter, Schiemann, Kai, Boettcher, Henning, Heinrich, Timo, Seyfried, Christoph, Leibrock, Joachim, Van Amsterdam, Christoph, and Bartoszyk, Gerd. Preparation of benzofuranyloxyalkylammoalkylindoles as serotonin agonists and reuptake inhibitors. 2004. WO2004074281.
72. Hoelzemann, Guenter, Crassier, Helene, Boettcher, Henning, Heinrich, Timo, Schiemann, Kai, Leibrock, Joachim, Van Amsterdam, Christoph, Bartoszyk, Gerd, and Seyfried, Christoph. Preparation of indole derivatives as 5HT receptor antagonists. 2004. WO2004052886.
73. Gant, Thomas G. and Sarshar, Sepehr. Preparation of deuterated aminoethylindolylmethylsulfonamides as serotonin 5-HT1B and/or 5-HT1D receptor modulators. 2008. WO2008049116.
74. Bakker, Cornells. Process for the preparation of 3-amino-8-(1- piperazinyl)-2H-1-benzopyran-2-one and its salts and solvates. 2005. WOUS 2005215566.
75. Bakker, Cornells, Glennon, Jeffrey C., Hesselink, Mayke B., Thaete, Claudia, Mccreary, Andrew, and Van, Scharrenburg Gustaaf J. M. Preparation of 1-[2H-1-benzopyran-2-one-8-yl] piperazine derivatives for the treatment of pain. 2005. WOUS 20050215567.
76. Bakker, Cornells, Glennon, Jeffrey C., Hesselink, Mayke B., Thaete, Claudia, Mccreary, Andrew, and Van, Scharrenburg Gustaaf J. M. Preparation of 1-[2H-1-benzopyran-2-one-8-yl]piperazine derivatives for the treatment of movement disorders. 2005. WOUS 2005215551.
77. Pfizer pipeline as of 28 February 2008. 2008. Ref Type: Internet Communication.
78. GSK pipeline 2007. 2009. Ref Type: Internet Communication.
79. 163090 Phase I study. 2008. Ref Type: Internet Communication.
80. GSK Pipeline 2008. 2008. Ref Type: Internet Communication.
81. G. W. John, P. J. Pauwels, M. Perez, S. Halazy, B. Le Grand, Y. Verscheure, J. P. Valentin, C. Palmier, T. Wurch, P. Chopin, M. Marien, M. S. Kleven, W. Koek, M. B. Assie, E. Carilla-Durand, J. P. Tarayre, and F. C. Colpaert, F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J. Pharmacol. Exp. Ther., 1999, 290, 83-95.
82. Dukat, M. Donitriptan (Pierre Fabre) Curr. Opin. Investig. Drugs, 2001, 2, 415-418.
83. Waeber, C. Emerging drugs in migraine treatment. Expert. Opin. Emerg. Drugs, 2003, 8, 437-456.
84. Treximet. 2009. Ref Type: Internet Communication.
85. Stewart, J. T. Abstracts and Citations, Headache: J. Head Face Pain, 2001, 47, 1234-1244.
86. TGBAOlAD: Fabre Kramer company website 2009. Ref Type: Internet Communication.